1. Home
  2. PHI vs GKOS Comparison

PHI vs GKOS Comparison

Compare PHI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PHI

PLDT Inc. Sponsored ADR

HOLD

Current Price

$21.79

Market Cap

4.7B

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$110.62

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHI
GKOS
Founded
1928
1998
Country
Philippines
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical/Dental Instruments
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.4B
IPO Year
1953
2015

Fundamental Metrics

Financial Performance
Metric
PHI
GKOS
Price
$21.79
$110.62
Analyst Decision
Hold
Strong Buy
Analyst Count
1
14
Target Price
N/A
$127.71
AVG Volume (30 Days)
49.6K
658.4K
Earning Date
11-11-2025
02-19-2026
Dividend Yield
5.53%
N/A
EPS Growth
9.36
N/A
EPS
2.32
N/A
Revenue
$3,761,997,877.00
$469,820,000.00
Revenue This Year
$2.70
$31.15
Revenue Next Year
$2.64
$24.15
P/E Ratio
$9.26
N/A
Revenue Growth
1.69
30.38
52 Week Low
$18.61
$73.16
52 Week High
$25.12
$163.71

Technical Indicators

Market Signals
Indicator
PHI
GKOS
Relative Strength Index (RSI) 57.06 54.91
Support Level $21.50 $115.07
Resistance Level $22.16 $117.94
Average True Range (ATR) 0.34 2.72
MACD -0.04 -1.03
Stochastic Oscillator 66.96 25.00

Price Performance

Historical Comparison
PHI
GKOS

About PHI PLDT Inc. Sponsored ADR

PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: